The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
The Center of Gerontology and Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
J Am Med Dir Assoc. 2019 Jan;20(1):53-57. doi: 10.1016/j.jamda.2018.04.012. Epub 2018 Jun 13.
The Mini Sarcopenia Risk Assessment (MSRA), a new sarcopenia screening tool, has 2 versions: MSRA-7 (full version, 7 items) and MSRA-5 (short version, 5 items). We aimed to compare the diagnostic values of MSRA-7 and MSRA-5 to SARC-F for screening sarcopenia.
A diagnostic accuracy study.
A community in Chengdu, China.
Older adults.
Muscle mass, strength, and physical performance were tested using a bioimpedance analysis (BIA) device, handgrip strength, and walking speed, respectively. Using the Asian Working Group for Sarcopenia (AWGS) criteria as the gold standard, the sensitivity/specificity analyses of the 3 scales were assessed. Receiver operating characteristic (ROC) curves and area under the ROC curves (AUC) were used to compare the overall diagnostic accuracy of the 3 scales.
We recruited 384 participants. Against the AWGS criteria, SARC-F had a sensitivity of 29.5% and a specificity of 98.1%, and the MSRA-7 had a sensitivity of 86.9% and a specificity of 39.6%, whereas the MSRA-5 had a sensitivity of 90.2% and a specificity of 70.6%. The AUCs of SARC-F, MSRA-7, and MSRA-5 were 0.89 [95% confidence interval (CI), 0.86-0.92], 0.70 (95% CI, 0.65-0.74), and 0.85 (95% CI, 0.81-0.89), respectively. The differences in AUCs between SARC-F and MSRA-7 and in those between MSRA-7 and MSRA-5 were statistically significant (P <.001), but the difference between SARC-F and MSRA-5 was not statistically significant (P = .130).
MSRA-5 may serve as a novel screening tool for sarcopenia in Chinese community-dwelling older adults. SARC-F, a class screening tool, is also suitable for this population. MSRA-5 and SARC-F demonstrated a similar diagnostic accuracy in our study population. MSRA-5 has better sensitivity, whereas SARC-F has better specificity. However, the diagnostic value of MSRA needs to be further validated in different populations.
Mini Sarcopenia 风险评估（MSRA）是一种新的肌少症筛查工具，有 2 个版本：MSRA-7（完整版本，7 项）和 MSRA-5（简化版本，5 项）。我们旨在比较 MSRA-7 和 MSRA-5 与 SARC-F 筛查肌少症的诊断价值。
诊断准确性研究。
中国成都的一个社区。
老年人。
使用生物电阻抗分析（BIA）设备分别测试肌肉质量、力量和身体表现，使用握力和步行速度。使用亚洲肌少症工作组（AWGS）标准作为金标准，评估了 3 种量表的敏感性/特异性分析。使用受试者工作特征（ROC）曲线和 ROC 曲线下面积（AUC）比较了 3 种量表的整体诊断准确性。
我们招募了 384 名参与者。根据 AWGS 标准，SARC-F 的敏感性为 29.5%，特异性为 98.1%，MSRA-7 的敏感性为 86.9%，特异性为 39.6%，而 MSRA-5 的敏感性为 90.2%，特异性为 70.6%。SARC-F、MSRA-7 和 MSRA-5 的 AUC 分别为 0.89（95%CI，0.86-0.92）、0.70（95%CI，0.65-0.74）和 0.85（95%CI，0.81-0.89）。SARC-F 与 MSRA-7 和 MSRA-7 与 MSRA-5 的 AUC 差异均有统计学意义（P<.001），但 SARC-F 与 MSRA-5 的 AUC 差异无统计学意义（P=.130）。
MSRA-5 可作为中国社区居住的老年人肌少症的新型筛查工具。SARC-F，一种分类筛查工具，也适用于该人群。在我们的研究人群中，MSRA-5 和 SARC-F 的诊断准确性相似。MSRA-5 具有更好的敏感性，而 SARC-F 具有更好的特异性。然而，MSRA 的诊断价值需要在不同人群中进一步验证。
